Kilitch Drugs Share Price | Kilitch Drugs Stock Screener
KILITCH
Pharmaceuticals
Share Price NSE
₹205.52
▲
10.79 (5.54%)
Share Price BSE
₹189.35
▼
-7.05 (-3.59%)
As of July 1, 2026, the Kilitch Drugs share price (NSE: KILITCH) is ₹205.52 on NSE and ₹189.35 on BSE, up 5.54% from the previous close, with shares trading between ₹192.84 and ₹207.00, and a 52-week range of ₹124.45–₹400.25.
Analyse KILITCH share price history and track historical price performance.
Use the Kilitch Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Kilitch Drugs Market Cap
₹658.90 Cr.
KILITCH P/E Ratio (TTM)
22.43
Kilitch Drugs P/B Ratio
2.37
EPS (TTM)
₹8.91
Dividend Yield
-
Debt to Equity
0.21
KILITCH 52 Week High
₹400.25
Kilitch Drugs 52 Week Low
₹124.45
Operating Margin
25.00%
Profit Margin
16.67%
KILITCH Revenue (TTM)
₹90.00
EBITDA
₹23.00
Net Income
₹15.00
Total Assets
₹458.00
Total Equity
₹280.00
Kilitch Drugs Share Price Chart
Screen Kilitch Drugs share price with an interactive chart. Analyse KILITCH price trends and volatility across different timeframes.
Kilitch Drugs Company Profile - Fundamental Screener
Screen Kilitch Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for KILITCH shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE729D01010
Kilitch Drugs Balance Sheet Screener
Screen KILITCH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 458 | 313 | 240 | 220 | 210 | 203 | 143 | 144 | 128 | 113 |
| Current Assets | 222 | 174 | 146 | 126 | 114 | 80 | 56 | 65 | 63 | 49 |
| Fixed Assets | 189 | 64 | 62 | 64 | 65 | 30 | 32 | 32 | 33 | 33 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 59 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 280 | 201 | 176 | 151 | 140 | 130 | 121 | 123 | 113 | 101 |
| Share Capital | 35 | 16 | 16 | 16 | 16 | 16 | 15 | 15 | 14 | 13 |
| Reserves & Surplus | 245 | 186 | 160 | 131 | 121 | 112 | 103 | 106 | 96 | 88 |
Kilitch Drugs Income Statement Screener - Profit & Revenue Analysis
Screen Kilitch Drugs income statement and profit fundamentals.
Analyze KILITCH quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Kilitch Drugs share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90 | 55 | 56 | 46 | 63 | 58 | 53 | 36 | 45 | 35 | 42 | 37 | 47 | 31 | 31 |
| Expenses | 68 | 48 | 44 | 40 | 47 | 47 | 41 | 32 | 38 | 30 | 33 | 30 | 39 | 26 | 27 |
| EBITDA | 23 | 8 | 12 | 6 | 16 | 11 | 11 | 4 | 8 | 5 | 9 | 7 | 7 | 5 | 4 |
| Operating Profit % | 25.00% | 11.00% | 10.00% | 8.00% | 24.00% | 16.00% | 13.00% | 5.00% | 16.00% | 7.00% | 21.00% | 17.00% | 14.00% | 13.00% | 13.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 2 | 2 | 1 | 0 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 2 |
| Profit Before Tax | 20 | 6 | 9 | 4 | 14 | 8 | 10 | 2 | 5 | 3 | 7 | 5 | 5 | 3 | 2 |
| Tax | 5 | 1 | 1 | 1 | 4 | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 0 |
| Net Profit | 15 | 4 | 8 | 2 | 10 | 6 | 9 | 0 | 4 | 2 | 5 | 3 | 3 | 2 | 2 |
| EPS | 4.24 | 2.50 | 4.97 | 1.88 | 6.47 | 3.71 | 5.36 | 0.83 | 2.24 | 1.85 | 2.93 | 2.15 | 2.29 | 1.52 | 1.56 |
Kilitch Drugs Cash Flow Screener - Liquidity Fundamentals
Screen KILITCH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 18 | -2 | 3 | 6 | 46 | 5 | 0 | 1 | 1 | 17 |
| Investing Activities | -40 | -8 | 8 | -15 | -38 | -10 | -14 | -4 | -2 | -20 |
| Financing Activities | 13 | 9 | -1 | 7 | 2 | 1 | 17 | 6 | 0 | 0 |
| Net Cash Flow | -9 | -1 | 10 | -2 | 10 | -5 | 3 | 3 | 0 | -2 |
Kilitch Drugs Shareholding Pattern Screener
See Kilitch Drugs shareholding pattern with promoter, FII, and DII holdings.
Check Kilitch Drugs promoter holding and ownership changes for KILITCH on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 63.77% | 69.23% | 69.23% | 63.77% | 63.77% | 69.23% | 69.23% | 69.23% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 29.70% | 25.57% | 25.54% | 30.22% | 31.04% | 25.37% | 25.21% | 25.10% |
| Other Holding | 6.52% | 5.20% | 5.23% | 6.01% | 5.18% | 5.39% | 5.56% | 5.67% |
| Shareholder Count | 11,642 | 9,749 | 10,379 | 10,929 | 12,043 | 9,525 | 9,620 | 9,920 |
Kilitch Drugs Share Dividend Screener - Share Yield Analysis
Check Kilitch Drugs dividend history with payout and yield data.
View Kilitch Drugs dividend details including ex-dates and amounts for KILITCH stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.50 | 0.62% |
| 2018-March | ₹0.50 | 0.26% |
| 2017-March | ₹0.00 | 0.00% |
Kilitch Drugs Stock Index Membership
See which indices include Kilitch Drugs stock.
Check KILITCH index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Kilitch Drugs Market Events Screener - Corporate Actions
Get Kilitch Drugs corporate actions including splits, bonuses, and buybacks.
Check Kilitch Drugs stock events that may affect KILITCH share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 6.76% | ||
| Annual General Meeting | NA | 2.13% | ||
| 2026-05-15 | 2026-05-15 | Quarterly Result Announcement | NA | 0.35% |
| 2026-03-24 | 2026-03-24 | Bonus | 1:1 | -0.91% |
| 2026-03-13 | 2026-03-13 | Extraordinary General Meeting | NA | -11.19% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 10.00% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -2.38% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -0.01% |
| 2025-07-15 | 2025-07-15 | Rights | 2:23 | 15.19% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 4.81% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 2.20% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -6.35% |
Kilitch Drugs Competitors Screener - Peer Comparison
Screen KILITCH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 457,025 | 39.71 | 58,220 | 6.38% | 11,565 | 69.58 |
| Divis Laboratories | 179,377 | 69.89 | 10,560 | 8.73% | 2,520 | 55.41 |
| Torrent Pharmaceuticals | 161,381 | 75.43 | 13,886 | 20.34% | 2,138 | 70.39 |
| Cipla | 117,800 | 30.51 | 29,045 | 2.24% | 3,870 | 66.80 |
| Zydus Life Science | 114,771 | 22.41 | 26,720 | 13.65% | 5,242 | 66.88 |
| Dr Reddys Laboratories | 114,692 | 27.60 | 35,059 | 3.90% | 4,158 | 67.04 |
| Lupin | 113,211 | 21.14 | 27,488 | 19.98% | 5,345 | 71.73 |
| Mankind Pharma | 104,430 | 53.93 | 14,278 | 12.03% | 1,750 | 60.79 |
| Aurobindo Pharma | 93,240 | 26.86 | 33,385 | 3.21% | 3,376 | 70.76 |
| Laurus Labs | 83,262 | 93.55 | 6,868 | 22.01% | 890 | 71.63 |
Kilitch Drugs Company Announcements - News Screener
Screen KILITCH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-27 | Closure of Trading Window | - |
| 2026-06-17 | Announcement Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 - Commencement Of Nutraceutical Manufacturing Block Of Our New Plant | - |
| 2026-05-27 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-15 | Board Meeting Outcome for Submission Of Audited Standalone And Consolidated Financial Results For The Quarter Ended 31St March 2026 | - |
| 2026-05-15 | Audited Standalone And Consolidated Financial Results For The Quarter Ended 31St March 2026 | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-05-07 | Board Meeting Intimation for Considering And Approval Of The Audited Financial Results For The Quarter And Year Ended 31St March 2026 | - |
| 2026-04-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-25 | Board Meeting Outcome for Allotment Of Bonus Equity Shares | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-03-17 | Intimation Of Record Date Pursuant To Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-13 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-03-13 | Shareholder Meeting / Postal Ballot-Outcome of EGM | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-16 | Notice Of EGM | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-11 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-02-11 | Financial Results For The Quarter Ended 31St December 2025 | - |